Some of these provisions include improvements in the quality and efficiencies of health care delivery, providing more access to patient-centered care, and allowing for Medicare payments for certain specified diagnostic testing. Moreover, the Act establishes a nonprofit corporation — the Patient-Centered Outcomes Research Institute — to assist in the analysis of the health outcomes and the clinical effectiveness, risks, and benefits of various medical treatments.
In this Web conference, Foley Life Sciences attorneys reviewed some of the key provisions in HR3590 that will have a direct impact on the business models and growth of the personalized medicine industry, discussed the potential opportunities, and reviewed the implications of the GINA Act of 2008, which will be closely tied to the provisions in the Act.
Foley speakers:
- Antoinette Konski, Partner, Foley & Lardner LLP
- Judy Waltz, Partner, Foley & Lardner LLP
Personalized Medicine and Health Care Reform: Realizing the Promise is part of the Health Care Reform: What’s In It For The Life Sciences Industry Web Conference Series.